Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Preoperative Levels of Matrix Metalloproteinase-7 and -9 and Tissue Inhibitor of Matrix Metalloproteinase-1 Relation to Pathologic Parameters in Bladder Carcinoma Patients

  • Gunes, Mustafa (Department of Urology, Yuzuncu Yil University Medical Faculty) ;
  • Kemik, Ahu Serap (Department of Biochemistry, Cerrahpasa Medical Faculty, University of Istanbul) ;
  • Pirincci, Necip (Department of Urology, Yuzuncu Yil University Medical Faculty) ;
  • Gecit, Ilhan (Department of Urology, Yuzuncu Yil University Medical Faculty) ;
  • Taken, Kerem (Urology Clinic of Van State Hospital) ;
  • Yuksel, Mehmet Bilgehan (Department of Urology, Celal Bayar University Medical Faculty) ;
  • Kaba, Mehmet (Urology Clinic of Van State Hospital) ;
  • Eryilmaz, Recep (Department of Urology, Yuzuncu Yil University Medical Faculty)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Our aim was to test the hypothesis that preoperative serum levels of matrix metalloproteinase-7 (MMP-7) and -9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) levels correlate with pathological features. Serum levels of MMP-7, and MMP-9 and TIMP-1 were determined in 90 bladder cancer patients and 40 healthy controls using an enzyme linked immunosorbent assay. Preoperative serum MMP-7 and MMP-9 levels were significantly higher in cancer patients than control groups (p<0.001). In contast, serum TIMP-1 levels were lower (p<0.001). Alteration in MMP-7, and MMP-9, and TIMP-1 production may contribute to tumor angiogenesis and be associated with clinic-pathological features.

Keywords

References

  1. Anton-Culver H, Lee-Feldstein A, Taylor TH (1992). Occupation and bladder cancer risk. Am J Epidemiol, 136, 89-94.
  2. Andersen JB, Aaboe M, Borden EC, et al (2006). Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer, 94, 1465-71. https://doi.org/10.1038/sj.bjc.6603099
  3. Cheng HC, Yang HB, Chang WL, et al (2012). Expressions of MMPs and TIMP-1 in gastric ulcers may differentiate H. pylori-infected from NSAID-related ulcers. Sci World J, 10, 539316.
  4. Cornelius LA, Nehring LC, Harding E, et al (1998). Matrix metalloporteinases generate angiostatin: effect of neovascularization. J Immunol, 161, 6845-52.
  5. Durkan GC, Nutt JE, Marsh C, et al (2003). Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clin Cancer Res, 9, 2576-82.
  6. Egeblad M, Werb Z (2009). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74.
  7. Guan KP, Hou SK, Yan Z, Ye HY (2003). Serum levels of endostatin and MMP-9 associated with high-stage and grade primary transitional cell carcinoma of the bladder cancer. Urology, 61, 719-23. https://doi.org/10.1016/S0090-4295(02)02429-9
  8. Hashimoto K, Kihira Y, Matuo Y, Usui T (1998). Expression MMP-7 and TIMP-1 in human prostate. J Urol, 160, 1872-6. https://doi.org/10.1016/S0022-5347(01)62435-2
  9. Hurst NG, Stocken DD, Wilson S, et al (2007). Elevated serum MMP-9 concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer, 97, 971-77. https://doi.org/10.1038/sj.bjc.6603958
  10. Hayakawa T, Yamashita K, Tanzawa K, et al (1992). Growth-promoting activity of tissue inhibitor of matrix metalloproteinase-1 for a wide range a cells. A possible new growth factor in serum. FEBS Lett. 298, 29-32. https://doi.org/10.1016/0014-5793(92)80015-9
  11. Johansen JL, Cohen SM (1997) Epidemiology and etiology of bladder cancer. Semin Surg Oncol, 13, 291-8. https://doi.org/10.1002/(SICI)1098-2388(199709/10)13:5<291::AID-SSU2>3.0.CO;2-8
  12. Kanayama H (2001) Matrix metalloproteinases and bladder cancer. J Med Invest, 48, 31-43.
  13. Koss LG, Deitch D, Ramathan R, Sherman AB (1985) Diagnostic value of cytology of voided urine. Acta Cytol, 29, 810-6.
  14. Laleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR (2002). Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases. J Cell Sci, 115, 3427-8.
  15. Leelawat K, Narong S, Wannaprasert J, Ratanashu T (2010). Prospective study of MMP-7 levels in the cholangiocarcainoma. World J Gastro, 16, 4697-703. https://doi.org/10.3748/wjg.v16.i37.4697
  16. Lipton A, Ali S, Demers L, et al (2007). Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 109, 1933-8. https://doi.org/10.1002/cncr.22637
  17. Li G, Fridman R, Kim HR (1999). TIMP-1 inhibits apopotosis of human breast epithelial cells. Cancer Res, 59, 6267-75.
  18. Martinez-Fernandez A, Garcia-Albeniz X, Pineda E, et al (2009). Serum matrilysin levels predict outcome curatively resected colorectal cancer patients. Ann Surg Oncol, 16, 1412-20. https://doi.org/10.1245/s10434-009-0405-9
  19. McQuibban GA, Gong JH, Wong JB, et al (2000). Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science, 289, 1202-06. https://doi.org/10.1126/science.289.5482.1202
  20. McQuibban GA, Butler GS, Gong JH, et al (2001). Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem, 276, 43503-8. https://doi.org/10.1074/jbc.M107736200
  21. Murray D, Morrin M, Mc Donnel S (2004) Increased invasion and expression of MMP-9 in human colorectal lines by a CD44-dependent mechanism. Anticancer Res, 24, 489-94.
  22. Naruo S, Kanayama H, Takigawa H (1994) Serum levels of TIMP-1 in bladder cancer patients. Int J Urol, 1, 228-31 https://doi.org/10.1111/j.1442-2042.1994.tb00040.x
  23. Park HD, Kang ES, Kim JW, et al (2012). Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics, 12, 3590-7. https://doi.org/10.1002/pmic.201200101
  24. Ray JM, Stetler-Stevenson WG (1994) The role of matrix metalloproteinase and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J, 7, 2062-72.
  25. Sharma S, Ksheersagar P, Sharma P (2009) Diagnosis and treatment of bladder cancer. Am Family Physician, 80, 717-23.
  26. Sheu BC, Hsu SM, Ho HN, et al (2001). A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res, 61, 237-42.
  27. Slaton JW, Millikan R, Inoue K, et al (2004). Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated cystectomy and chemotherapy. J Urol, 171, 570-4. https://doi.org/10.1097/01.ju.0000108845.91485.20
  28. Szarvas T, Jager T, Becker M, et al (2011). Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res, 17, 325-32. https://doi.org/10.1007/s12253-010-9320-4
  29. Szarvas T, Becker M, vom Dorp F, et al (2010). MMP-7 as a marker of metastasis and predictor of poor urvival in bladder cancer. Cancer Sci, 101, 1300-8.l https://doi.org/10.1111/j.1349-7006.2010.01506.x
  30. Szarvas T, Singer BB, Becker M, et al (2010). Urinary MMP-7 level is associated with the presence of metastasis in bladder cancer. BJU Int, 7, 1069-73.
  31. Torii A, Kodera Y, Uesaka K, et al (1997). Plasma concentration of MMP-9 in gastric cancer. Br J Cancer, 84, 133-6.
  32. Wallard MJ, Pennington CJ, Veerakumarasivam A, et al (2006). Comprehensive profiling and localization of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer, 94, 569-77. https://doi.org/10.1038/sj.bjc.6602931
  33. Wu ZS, Wu Q, Yang JH, et al (2008). Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer, 122, 2050-6. https://doi.org/10.1002/ijc.23337
  34. Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM (2002). Identification of novel matrix metalloproteinase-7 cleavage sites in murine and human Fas ligand. Arch Biochem Biophys, 408, 155-61. https://doi.org/10.1016/S0003-9861(02)00525-8
  35. Vasala K, Paakko P, Turpeenniemi-Hujanen T (2008). MMP-9 immunorecative protein in urinary bladder cancer: a marker of favorable prognosis. Anticancer Res, 28, 1757-67.
  36. Yang B, Su K, Gao J, Rao Z (2012) Expression and prognostic value of matrix metalloproteinase-7 in colorectal cancer. Asian Pac J Cancer Prev, 13, 1049-52. https://doi.org/10.7314/APJCP.2012.13.3.1049
  37. Yeh YC, Sheu BS, Cheng HC, et al (2010). Elevated serum MMP-3 and -7 in H. pylori-related gastric cancer can be markers biomarkers correlating with a poor survival. Dig Dis Sci, 55, 1649-57. https://doi.org/10.1007/s10620-009-0926-x
  38. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T (2000). Serum MMP-2, and -9 and TIMP-1, -2 in lung cancer-TIMP-1 as prognostic marker. Anticancer Res, 20, 1311-6.
  39. Yukawa N, Yoshikawa T, Akaike M, et al (2007). Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology, 72, 205-8. https://doi.org/10.1159/000112827
  40. Zhou JH, Zhang B, Kernstine KH, Zhong L (2011). Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastro, 17, 1373-8. https://doi.org/10.3748/wjg.v17.i10.1373

Cited by

  1. Elevated matrix metalloproteinase-9 expression may contribute to the pathogenesis of bladder cancer vol.11, pp.3, 2016, https://doi.org/10.3892/ol.2016.4187